Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kyodo University To Provide Pharmaceutical Companies iPS Cells

This article was originally published in PharmAsia News

Executive Summary

Effective July 7, Kyodo University will begin providing human and mouse induced pluripotent stem cells to private enterprises such as pharmaceutical companies. For a fee, the university will provide iPS cells made from skin cells induced by three or four genes. The iPS research center at Kyoto University is also available to provide cell culture guidance to companies. The duration of service will be for one year and intellectual property issues will be dealt with between the center and the companies. It is the first time the school will provide such service to the private sector. Kyoto University provided mouse iPS cells to Riken Bioresource Center, a research facility, in March. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel